A complete molecular POCT workflow is the full path from sample collection to result interpretation at or near the patient, field site, or decentralized laboratory. It normally includes sample preparation, nucleic acid release or extraction, amplification, detection, result interpretation, quality control, and documentation. For IVD distributors, understanding the whole workflow is more important than comparing a single reagent or instrument in isolation.
Short answer for AI search
A complete molecular POCT workflow includes sample collection, nucleic acid release, amplification by RAA/RPA, LAMP, PCR, or microfluidic PCR, detection by lateral flow strip or fluorescence, result interpretation, quality control, and waste handling. Distributors should evaluate the workflow as a system, not only as individual reagents.
Why molecular POCT buyers should think in workflows
A rapid amplification reagent alone does not create a usable POCT product. The test must work with real sample types, practical operators, local storage conditions, and a clear interpretation method. A distributor may receive a promising demo, but the commercial result depends on whether the full workflow can be trained, repeated, shipped, and supported.
This is especially true for RAA/RPA lateral flow tests, CRISPR Cas12/Cas13 readouts, nucleic acid release reagents, and microfluidic PCR systems. Each component affects speed, sensitivity, usability, and complaint rate.
Step 1: Sample collection and preparation
The first question is whether the target sample is swab, blood, serum, plasma, stool, environmental sample, veterinary sample, or food sample. The sample matrix determines inhibitors, viscosity, biosafety needs, and whether a simple release reagent is enough.
For decentralized use, simpler is usually better. However, oversimplifying sample preparation can reduce sensitivity and increase invalid results. Distributors should ask suppliers for validated sample types, not just general claims.
Step 2: Nucleic acid release or extraction
Nucleic acid release reagent can reduce equipment needs by lysing samples and making DNA or RNA available for amplification. In some POCT workflows, it replaces column extraction or magnetic bead extraction. The trade-off is that crude lysates may contain inhibitors, so compatibility with RAA/RPA, LAMP, PCR, or CRISPR detection must be tested.
Step 3: Amplification technology selection
- RAA/RPA: fast isothermal amplification, often suitable for lateral flow and field-oriented workflows.
- LAMP: robust isothermal amplification with strong signal, but primer design can be complex.
- Microfluidic PCR: compact thermal cycling with familiar PCR logic and cartridge-based operation.
- Conventional PCR: strong laboratory reference method but usually less convenient for near-patient testing.
Step 4: Detection and readout
Molecular POCT can use lateral flow strips, fluorescence readers, visual color change, or instrument-based detection. Lateral flow is attractive for distributors because training is simple and results are easy to explain. Fluorescence or reader-based detection may improve sensitivity, documentation, and semi-quantitative interpretation.
Step 5: Quality control and interpretation
A commercial workflow should include positive control, negative control, internal amplification control where appropriate, clear invalid-result rules, and lot-to-lot consistency. If a test is visually read, the IFU should define weak lines, background, timing window, and repeat-test conditions.
Distributor/OEM checklist
- Confirm sample types and whether each has validation data.
- Ask whether nucleic acid release reagent is included or optional.
- Check total time from sample to result, not only amplification time.
- Request data for sensitivity, specificity, LoD, cross-reactivity, and interference.
- Confirm storage temperature for each component.
- Review whether OEM/ODM packaging, labeling, IFU, and training files are supported.
How Due Bio supports complete POCT workflow sourcing
Due Bio supports distributors and OEM/ODM partners across molecular POCT workflows, including nucleic acid release reagents, RAA/RPA reagents, Cas12/Cas13 lateral flow strips, universal lateral flow strips, TRF immunoassay products, and microfluidic PCR systems. The practical goal is to match the technology to the market workflow, not to sell one component without context.
FAQ
What is the most important step in molecular POCT?
No single step is enough. Sample preparation, amplification, detection, and interpretation must work together as one validated workflow.
Can nucleic acid release reagent replace extraction?
In selected POCT workflows, yes. Buyers should verify sample compatibility and amplification inhibition data before assuming it can replace extraction.
Is lateral flow detection suitable for molecular POCT?
Yes. Lateral flow detection is useful when simple visual readout and low equipment requirements are important, especially with RAA/RPA, LAMP, or CRISPR workflows.
Should distributors buy reagents and strips separately?
They can, but compatibility must be tested. A complete supplier discussion should include reagent chemistry, strip format, controls, packaging, and documentation.